FSD Pharma Files Management Information Circular for Proposed Arrangement with Celly Nu

About this update from Quantum Biopharma Ltd. Subordinate Voting Shares Class B

[{"type":"text","content":"FSD Pharma Files Management Information Circular for Proposed Arrangement with Celly NuTORONTO, ON / ACCESSWIRE / October 23, 2023 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) (\"FSD Pharma\" or the \"Company\"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, and Celly Nutrition Corp. (\"Celly Nu\") announced today that FSD Pharma has filed on www.sedarplus.ca its management information circular (the \"Circular\") and related materials in connection with the special meeting (the \"Meeting\") of FSD Pharma Securityholders (as defined in the Company's press release dated October 5, 2023) to be held on November 20, 2023, at 1:00 p.m. (Toronto time), as a virtual meeting through the AGM Connect meeting platform at www.agmconnect.com/fsdpharma2023, to approve, among other things, the previously-announced plan of arrangement (the \"Arrangement\") pursuant to which FSD Pharma proposes to distribute a portion of its shareholdings of Celly Nu to certain FSD Pharma Securityholders, and as more particularly described in the Circular. Filing of Circular for the MeetingThe Circular provides important information regarding the Arrangement and related matters, including the background to the Arrangement, the reasons for the recommendation of the board of directors of FSD Pharma (the \"Board\"), voting procedures and other matters to be considered and if deemed advisable approved at the Meeting. FSD Pharma Securityholders are urged to read the Circular and its appendices carefully and in their entirety. The Circular and the related materials in connection with the Meeting are being provided to FSD Pharma Securityholders in compliance with applicable laws and the interim order of The Ontario Superior Court of Justice (Commercial List) granted on October 11, 2023 which is included in the Circular, which is available under FSD Pharma's issuer profile on SEDAR+ at www.sedarplus.ca.FSD Pharma Securityholders are cautioned that there is no certainty that the Arrangement or any of the related matters discussed in the Circular will be completed as currently proposed or at all. An investment in securities of Celly should be considered highly speculative and prospective investors should consult their advisors prior to making any investment decisions.About FSD PharmaFSD is a biopharmaceutic...

More updates from Quantum Biopharma Ltd. Subordinate Voting Shares Class B